{"organizations": [], "uuid": "30f2ead893db607ecc1e207633a9f7f8ecba73f9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-immunogen-announces-first-patient/brief-immunogen-announces-first-patient-dosed-in-phase-1-study-of-imgn632-for-hematological-malignancies-idUSFWN1OZ0PR", "country": "US", "domain_rank": 408, "title": "BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T15:46:00.000+02:00", "replies_count": 0, "uuid": "30f2ead893db607ecc1e207633a9f7f8ecba73f9"}, "author": "", "url": "https://www.reuters.com/article/brief-immunogen-announces-first-patient/brief-immunogen-announces-first-patient-dosed-in-phase-1-study-of-imgn632-for-hematological-malignancies-idUSFWN1OZ0PR", "ord_in_thread": 0, "title": "BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "immunogen", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "hematological malignancies reuters staff", "sentiment": "none"}, {"name": "immunogen inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 1:47 PM / Updated 9 minutes ago BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies Reuters Staff 1 Min Read \nJan 4 (Reuters) - ImmunoGen Inc: \n* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T15:46:00.000+02:00", "crawled": "2018-01-04T16:11:50.002+02:00", "highlightTitle": ""}